Zoetis Inc. (ZTS)
Zoetis is the world's largest animal health company, creating medicines, vaccines, and diagnostic tools for pets and livestock.
Is Zoetis Inc. a good stock for a UK beginner?
The honest version: Zoetis is the world's largest animal health company, creating medicines, vaccines, and diagnostic tools for pets and livestock.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Long-term growth in the 'humanisation' of pets driving premium care.
Significant regulatory hurdles or a major shift in farming practices.
What does Zoetis Inc. do?
Zoetis focuses on keeping our furry friends and farm animals healthy, selling everything from flea treatments to complex vaccines. Selling these products to vets and livestock farmers across the globe is what pays the bills. So much rides on how much pet owners continue to spend on their animals' healthcare, even when household budgets are feeling a bit tight.
On our factor screen it looks strongest on income and quality, and weakest on momentum.
- ✓Pays a dividend - about 2.7% a year
- ✓Growing - revenue up about 3% over the year
- ✓Very profitable - turns about 28% of sales into profit
- !Carries a lot of debt - roughly 2.9x its equity
- ✓Strong return on shareholder money (ROE 68%)
- Dominant position in a stable, essential industry.
- Very high profit margins showing strong control over costs.
- Products are generally considered 'must-haves' rather than luxuries.
- Growth screens low (27/100)
- Momentum screens low (12/100)
- Changes in government regulations regarding animal medicine.
- Outbreaks of disease in livestock that could disrupt supply chains.
- Economic downturns leading to owners choosing cheaper, non-branded alternatives.
What do Zoetis Inc.'s numbers mean?
How much money does Zoetis Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Zoetis Inc. pay a dividend?
Yes - Zoetis Inc. currently pays a dividend of about 2.7% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Zoetis Inc. report earnings, and how did recent quarters go?
Zoetis Inc. is next scheduled to report on about 2026-08-06 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-07 | $1.62 | $1.53 | Missed -5% |
| 2026-02-12 | $1.40 | $1.48 | Beat +5% |
| 2025-11-04 | $1.62 | $1.70 | Beat +5% |
| 2025-08-05 | $1.61 | $1.76 | Beat +9% |
| 2025-05-06 | $1.40 | $1.48 | Beat +6% |
| 2025-02-13 | $1.36 | $1.40 | Beat +3% |
Across the last 6 quarters here, Zoetis Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Zoetis Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Zoetis Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Dominant position in a stable, essential industry.
- Very high profit margins showing strong control over costs.
- Products are generally considered 'must-haves' rather than luxuries.
- Recent share price performance has been quite weak.
- Growth in revenue has slowed down recently.
- High reliance on the willingness of pet owners to pay for premium care.
- Changes in government regulations regarding animal medicine.
- Outbreaks of disease in livestock that could disrupt supply chains.
- Economic downturns leading to owners choosing cheaper, non-branded alternatives.
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained period of double-digit revenue growth.
- A major, successful acquisition that changes the company's scale.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.